Author

Carmen Diana Schweighofer

Observed names: C D Schweighofer, C Schweighofer, C. Schweighofer, C.D. Schweighofer, Carmen D Schweighofer, Carmen D. Schweighofer, Carmen Schweighofer, Schweighofer CD, Schweighofer, C., Schweighofer, C. D., Schweighofer, Carmen, Schweighofer, Carmen Diana

Observed institutions: The University of Texas MD Anderson Cancer Center, University of Cologne, Helmholtz Munich, University Hospital Cologne, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Deutsche CLL Studiengruppe (DCLLSG), Technical University of Munich, Ludwig-Maximilians-Universität München

OpenAlex ID: A5034764934

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

2011 · Kirsten Fischer, Paula Cramer, et al. · Journal of Clinical Oncology · 379

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

2009 · Barbara F. Eichhorst, Raymonde Busch, et al. · Blood · 334

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

2004 · C-M Wendtner, M Ritgen, et al. · Leukemia · 265

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

2008 · Carmen D. Schweighofer, Matthias Ritgen, et al. · British Journal of Haematology · 101

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

2008 · Kirsten Fischer, Stephan Stilgenbauer, et al. · Blood · 99

Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors

2002 · Clemens-Martin Wendtner, David M. Kofler, et al. · Blood · 78

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies

2012 · I Leskov, C P Pallasch, et al. · Oncogene · 50

PDF

Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features

2011 · Yang O. Huh, Carmen D. Schweighofer, et al. · American Journal of Clinical Pathology · 44

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

2013 · Carmen D Schweighofer, Florence Cymbalista, et al. · Blood · 41

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients

2011 · Hatice Duzkale, Carmen D. Schweighofer, et al. · Blood · 34

PDF

Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy

2006 · Barbara F. Eichhorst, Raymonde Busch, et al. · British Journal of Haematology · 32

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

2007 · Barbara F. Eichhorst, Raymonde Busch, et al. · Blood · 31

Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia

2012 · Carmen D. Schweighofer, Kevin R. Coombes, et al. · Journal of Molecular Diagnostics · 24

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

2011 · Carmen D. Schweighofer, Kevin R. Coombes, et al. · PLoS ONE · 24

PDF

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

2007 · Kirsten Fischer, Stephan Stilgenbauer, et al. · Blood · 22

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

2010 · Carmen Schweighofer · OncoTargets and Therapy · 21

PDF

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

2006 · C. Schweighofer, M. Ritgen, et al. · Blood · 21

The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy

2010 · Carmen D. Schweighofer, Yang O. Huh, et al. · International Journal of Cancer · 17

PDF

Lyme Disease in a Patient with Chronic Lymphocytic Leukemia Mimics Leukemic Meningeosis

2007 · Carmen D. Schweighofer, Gerd Fätkenheuer, et al. · Oncology Research and Treatment · 9

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

2007 · Kirsten Fischer, Carmen D. Schweighofer, et al. · Blood · 8

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

2012 · Carmen D. Schweighofer, Armin Tuchscherer, et al. · Cancer Immunology Immunotherapy · 7

Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

2004 · Matthias Ritgen, C. Schweighofer, et al. · Blood · 6

Eradication of minimal residual disease in chronic lymphocytic leukemia

2008 · Carmen Diana Schweighofer, Michael Hallek, et al. · Current Hematologic Malignancy Reports · 2

More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group

2014 · Petra Langerbeins, Raimunde Busch, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 1

*104 LDOC1 mRNA Is Differentially Expressed in Chronic Lymphocytic Leukemia and Predicts Overall Survival in Untreated Patients

2011 · Hatice Duzkale, Carmen D. Schweighofer, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Works count: 38

Citation count: 1,654

H-index: 17

I10-index: 18